Trial
NCT05226780
Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
Neurocrine Biosciences
Collaborators
—
Condition
SCN8A Developmental and Epileptic Encephalopathy Syndrome
Intervention
NBI-921352
Why stopped
This study was prematurely terminated due to sponsor decision.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-05-27